KU 5039

Drug Profile

KU 5039

Alternative Names: KU-5039

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kareus Therapeutics
  • Class Antihyperglycaemics; Insulin sensitisers; Small molecules
  • Mechanism of Action Adenylate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Insulin resistance; Type 2 diabetes mellitus

Most Recent Events

  • 18 Apr 2016 Phase-I clinical trials in Insulin resistance in USA (PO)
  • 18 Apr 2016 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 13 Feb 2014 KU 5039 is available for licensing as of 13 Feb 2014. http://www.kareustherapeutics.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top